Guardant Health, Inc. (GH)
After hours:
| Previous close | 26.24 |
| Open | 26.14 |
| Bid | 25.34 x 800 |
| Ask | 25.39 x 800 |
| Day's range | 25.07 - 26.27 |
| 52-week range | 15.81 - 41.06 |
| Volume | |
| Avg. volume | 2,178,938 |
| Market cap | 3.103B |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., May 17, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units ("RSUs") representing 215,601 shares of its common stock to 94 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 98,076 shares of its common stock to three new non-executive employees with a grant date
- Business Wire
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
PALO ALTO, Calif., May 16, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.
- Business Wire
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
PALO ALTO, Calif., May 09, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024.
